ASO Visual Abstract: Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy.

Autor: So A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yi M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Simons JM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Erasmus University Medical Center, Rotterdam, The Netherlands., Kuerer HM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Caudle A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DeSnyder SM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedrosian I; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nead KT; Department of Radiation Oncology and Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chavez-MacGregor M; Department of Health Services Research and Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Teshome M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; UCLA Medical Center, Los Angeles, CA, USA., Hunt KK; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. khunt@mdanderson.org.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Significance of Residual Nodal Disease in Clinically Node-Negative Breast Cancer After Neoadjuvant Chemotherapy.

Autor: So A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yi M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Simons JM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Kuerer HM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Caudle A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DeSnyder SM; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedrosian I; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nead KT; Department of Radiation Oncology and Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chavez-MacGregor M; Department of Health Services Research and Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Teshome M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; UCLA Medical Center, Los Angeles, CA, USA., Hunt KK; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. khunt@mdanderson.org.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.

PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects - A Phase 2 Clinical Trial.

Autor: Shaitelman SF; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: sfshaitelman@mdanderson.org., Le-Petross H; Department of Breast Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas., Raso MG; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Swanson DM; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas., Schalck AP; Department of Genomics, University of Texas MD Anderson Cancer Center, Houston, Texas., Contreras A; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Yang F; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Muruganandham M; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas., Zhao GZ; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas., Sawakuchi GO; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas., Kim LH; Department of Radiation Oncology, MD Anderson Cancer Center at Cooper, Camden, New Jersey., Batra H; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas., Smith BD; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Stauder MC; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Woodward WA; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Reddy JP; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Litton JK; Department of Clinical Research, University of Texas MD Anderson Cancer Center, Houston, Texas., Thompson A; Section of Breast Surgery, Division of Surgical Oncology, Baylor College of Medicine, Houston, Texas., Bedrosian I; Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas., Mittendorf EA; Division of Breast Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Aug 13. Date of Electronic Publication: 2024 Aug 13.

Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.

Autor: Wang J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hchen7@mdanderson.org.; Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 085, G1.3617B, Houston, TX, 77030, USA. hchen7@mdanderson.org., Koenig J; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Indiana University School of Medicine, Indianapolis, IN, 46202, USA., Wu Y; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedrosian I; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Arun B; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ding Q; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khazai L; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Resetkova E; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huo L; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sneige N; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albarracin C; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. calbarra@mdanderson.org.; Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 085, G1.3617A, Houston, TX, 77030, USA. calbarra@mdanderson.org.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Jan; Vol. 203 (1), pp. 73-83. Date of Electronic Publication: 2023 Sep 26.

Lobular Neoplasia Diagnosed by MRI-Guided Breast Biopsy: Identifying Upgrade Rate to Malignancy and Outcomes of Clinical and Surgical Management.

Autor: Everidge SA; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Teshome M; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tamirisa N; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sun S; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Adesoye T; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nia E; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bevers T; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedrosian I; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel M; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Singh P; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Psingh6@mdanderson.org.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2024 Apr; Vol. 31 (4), pp. 2224-2230. Date of Electronic Publication: 2023 Dec 20.